Selective clearance of monoclonal antibodies via the mannose receptor is dependent on glycan pairing

1. Crescioli, S. et al. Antibodies to watch in 2025 ABSTRACT. MAbs [Internet]. ;17(1). (2025). Available from: https://doi.org/10.1080/19420862.2024.2443538

2. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 5 (OCT), 1–17 (2014).

   Google Scholar 

3. Liu, L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 9 (1), 15–32 (2018).

   Google Scholar 

4. Ryman, J. T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst. Pharmacol. 6 (9), 576–588 (2017).

   Google Scholar 

5. Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7 (9), 715–725 (2007).

   Google Scholar 

6. Goetze, A. M. et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21 (7), 949–959 (2011).

   Google Scholar 

7. Zhou, Q. et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol. Bioeng. 99 (3), 652–665 (2008).

   Google Scholar 

8. Luo, S. & Zhang, B. Benchmark Glycan Profile of Therapeutic Monoclonal Antibodies Produced by Mammalian Cell Expression Systems. Pharm Res [Internet]. ;(0123456789). (2023). Available from: https://doi.org/10.1007/s11095-023-03628-4

9. Flynn, G. C., Chen, X., Liu, Y. D., Shah, B. & Zhang, Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol [Internet]. ;47(11–12):2074–82. (2010). Available from: https://doi.org/10.1016/j.molimm.2010.04.006

10. Liu, Y. D. & Flynn, G. C. Biologicals Effect of high mannose glycan pairing on IgG antibody clearance. Biologicals [Internet]. ;44(3):163–9. (2016). Available from: https://doi.org/10.1016/j.biologicals.2016.02.003

11. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8 (3), 226–234 (2009).

    Google Scholar 

12. Mastrangeli, R., Audino, M. C., Palinsky, W., Broly, H. & Bierau, H. The formidable challenge of controlling high Mannose-Type N-Glycans in therapeutic mAbs. Trends Biotechnol. 38 (10), 1154–1168 (2020).

    Google Scholar 

13. Tharmalingam, T., Wu, C. H., Callahan, S. & Goudar, C. T. A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture. Biotechnol. Bioeng. 112 (6), 1146–1154 (2015).

    Google Scholar 

14. Zupke, C. et al. Real-time product attribute control to manufacture antibodies with defined N-linked glycan levels. Biotechnol. Prog. 31 (5), 1433–1441 (2015).

    Google Scholar 

15. Meudt, M. et al. Comprehensive Analysis and Characterization of Glycan Pairing in Therapeutic Antibodies and Fc-Containing Biotherapeutics : Addressing Current Limitations and Implications for N-glycan impact. Eur J Pharm Biopharm [Internet]. ;114325. (2024). Available from: https://doi.org/10.1016/j.ejpb.2024.114325

16. Reusch, D. & Tejada, M. L. Fc glycans of therapeutic antibodies as critical quality attributes. Glycobiology 25 (12), 1325–1334 (2015).

    Google Scholar 

17. Higel, F., Seidl, A., Sörgel, F. & Friess, W. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm [Internet]. ;100:94–100. (2016). Available from: https://doi.org/10.1016/j.ejpb.2016.01.005

18. Edwards, E. et al. Strategies to control therapeutic antibody glycosylation during bioprocessing: synthesis and separation. Biotechnol. Bioeng. 119 (6), 1343–1358 (2022).

    Google Scholar 

19. Alessandri, L. et al. Increased serum clearance of oligomannose species present on a human IgG1 molecule. MAbs 4 (4), 509–520 (2012).

    Google Scholar 

20. Falck, D. et al. Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody. MAbs [Internet]. ;13(1). (2021). Available from: https://doi.org/10.1080/19420862.2020.1865596

21. Falck, D. et al. Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model. MAbs [Internet]. ;14(1). (2022). Available from: https://doi.org/10.1080/19420862.2022.2145929

22. Higel, F. et al. N-glycan PK profiling using a high sensitivity nanolcms Work-Flow with heavy stable isotope labeled internal standard and application to a preclinical study of an IgG1 biopharmaceutical. Pharm. Res. 32 (11), 3649–3659 (2015).

    Google Scholar 

23. Kanda, Y. et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (1), 104–118 (2007).

    Google Scholar 

24. Wright, B. A. & Morrison, S. L. Effect of altered Ca2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric Mouse-Human Immunoglobulin G1. J. Immunol. 160(7), 3393–3402 (1998).

25. Chen, X., Liu, D. & Flynn, G. C. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 19 (3), 240–249 (2009).

    Google Scholar 

26. Taylor, P. R., Gordon, S. & Martinez-Pomares, L. The mannose receptor: linking homeostasis and immunity through sugar recognition. Trends Immunol. 26 (2), 104–110 (2005).

    Google Scholar 

27. East, L. & Isacke, C. M. The mannose receptor family. Biochimica et Biophysica Acta 1572, 364–386 (2002).

28. Baumeister, J. et al. Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing. MAbs [Internet]. ;16(1):2400414. (2024). Available from: https://doi.org/10.1080/19420862.2024.2400414

29. Dashivets, T. et al. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One. 10 (12), 1–24 (2015).

    Google Scholar 

30. Gahoual, R. et al. Detailed characterization of monoclonal antibody receptor interaction using affinity liquid chromatography hyphenated to native mass spectrometry. Anal. Chem. 89 (10), 5404–5412 (2017).

    Google Scholar 

31. Wada, R., Matsui, M. & Kawasaki, N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs [Internet]. ;11(2):350–72. (2019). Available from: https://doi.org/10.1080/19420862.2018.1551044

32. Streit, M. et al. A visual cancer analysis tool for ranking and exploring genes, cell lines and tissue samples. Bioinformatics 35 (17), 3140–3142 (2019).

    Google Scholar 

33. Taylor, M. E. & Drickamer, K. Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor. J. Biol. Chem. 268 (1), 399–404 (1993).

    Google Scholar 

34. Yu, M. et al. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans. ;(August):475–87. (2017). Available from: https://teach.com/blog/six-snapchat-projects-for-a-classroom/

35. Liu, Y. D. & Flynn, G. C. Effect of high mannose glycan pairing on IgG antibody clearance. Biologicals [Internet]. ;44(3):163–9. (2016). Available from: https://doi.org/10.1016/j.biologicals.2016.02.003

36. Martinez-Pomares, L. The mannose receptor. J. Leukoc. Biol. 92 (6), 1177–1186 (2012).

    Google Scholar 

37. Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316, 612–616 (2007).

38. Wolf, B. et al. Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity. Immunology 166 (3), 380–407 (2022).

    Google Scholar 

39. Dasgupta, S. et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4 ؉. T Lymphocytes. 104 (21), 1–6 (2007).

    Google Scholar 

40. Wilhelm, J. G., Dehling, M. & Higel, F. High-selectivity profiling of released and labeled N-glycans via polar-embedded reversed-phase chromatography. Anal. Bioanal Chem. 411 (3), 735–743 (2019).

    Google Scholar 

Download references

Authors and Affiliations

1. Global Development CMC Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany

   Julia Baumeister, Maximilian Meudt, Michaela Blech & Fabian Higel

2. Institute of Pharmaceutical Biotechnology, Ulm University, Ulm, Germany

   Julia Baumeister & Frank Rosenau

3. Institute of Analytical and Bioanalytical Chemistry, Ulm University, Ulm, Germany

   Maximilian Meudt & Boris Mizaikoff

4. Global Non Clinical Safety and DMPK, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA

   Wei Wei & Lin-Zhi Chen

5. Institute of Applied Biotechnology, Biberach University of Applied Sciences, Biberach an der Riss, Germany

   Sybille Ebert

Contributions

J. B. designed the studies, generated the high-mannose enriched mAb material, performed the analytical characterization and developed the in vitro experiments (cell-based assay), analyzed and interpreted the data and wrote the first draft of the manuscript including figures and tables. M. M. supported the generation of the mAb material, developed analytical methods, supported the characterization work and provided feedback on the manuscript. W. W. designed and supervised the in vivo study, performed the LC-MS bioanalysis, analyzed and interpreted the data and contributed to the respective sections in the manuscript. L-Z.C. designed and supervised the in vivo study, analyzed and interpreted the data and contributed to the respective sections in the manuscript. S. E. provided scientific feedback to distinct parts of the study and reviewed and edited the manuscript. F. R. provided scientific feedback to distinct parts of the study and reviewed and edited the manuscript. B. M. provided scientific feedback to distinct parts of the study and reviewed and edited the manuscript. M. B. provided scientific feedback to distinct parts of the study and reviewed and edited the manuscript. F. H. conceptualized the study, contributed to the experimental design, supervised the study, supported data interpretation, and provided critical feedback on the manuscript.

Corresponding author

Correspondence to Fabian Higel.

Competing interests

Julia Baumeister, Maximilian Meudt, Wei Wei, Michaela Blech, Lin-Zhi Chen and Fabian Higel are employees of Boehringer Ingelheim GmbH & Co. KG, which is developing, manufacturing, and marketing biopharmaceutical products. Sybille Ebert, Frank Rosenau and Boris Mizaikoff declare no competing interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions